Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy

M. A. Ghetie, R. D. May, M. Till, J. W. Uhr, V. Ghetie, P. P. Knowles, M. Relf, A. Brown, P. M. Wallace, G. Janossy, P. Amlot, E. S. Vitetta, P. E. Thorpe

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Ricin A chain-containing immunotoxin (IT-As) specific for the human B-cell antigens, CD22 and CD19, were constructed using the monoclonal antibodies, HD6 and HD37, respectively. IT-As were prepared by coupling intact antibodies, F(ab')2, or Fab' fragments to native or chemically deglycosylated ricin A chain. The IT-As were then evaluated for cytotoxicity to normal and neoplastic human B-cells in vitro with the major objective of appraising their suitability for in vivo therapy of human B-cell tumors. The IT-As prepared with both the HD6 and HD37 antibodies were specifically toxic to normal B-cells and to most of the neoplastic B-cell lines tested. However, the IT-As prepared from HD6 were generally more potent than those prepared from HD37. On Daudi cells, to which the two antibodies bound in similar numbers and with similar affinities, IT-As prepared with intact HD6 antibody or its Fab' fragment were 10-fold and 1.5- to 4-fold more potent, respectively, than the corresponding HD37 IT-As. The IT-As constructed from intact HD6 antibody and native or deglycosylated A chain reduced protein synthesis in Daudi cells by 50% at a concentration of 1.2 x 10-11 M indicating that they were only 5-fold less toxic to the cells than ricin itself. Intact HD-37 IT-As produced equivalent inhibition of protein synthesis at 1.5 x 10-10 M. With both antibodies, IT-As constructed from the Fab' fragments were 10- to 20-fold less potent than their intact antibody counterparts. Different neoplastic B-cell lines varied in sensitivity to the IT-As. In most cases, their sensitivity correlated with the levels of CD19 and CD22 antigens expressed. Neither HD6 nor HD37 IT-As affected the ability of normal human bone marrow cells to form granulocyte-macrophage colony-forming units in soft agar, suggesting that both antigens are absent from these progenitor cells. Examination of sections of frozen human tissues using immunoperoxidase staining procedurs indicated that the antibodies did not bind to a panel of normal tissues lacking B-lymphocytes. These results suggest that HD6 and HD37 IT-As are candidates for in vivo therapy in humans with certain B-cell tumors. However, HD6 IT-As are more potent, reduce protein synthesis more completely, and hence appear to be the ITs of choice for treating tumors expressing the CD22 antigen.

Original languageEnglish (US)
Pages (from-to)2610-2617
Number of pages8
JournalCancer Research
Volume48
Issue number9
StatePublished - 1988

Fingerprint

Sialic Acid Binding Ig-like Lectin 2
CD19 Antigens
Ricin
Immunotoxins
B-Lymphocytes
Antibodies
Immunoglobulin Fab Fragments
Poisons
Therapeutics
Cell Line
Neoplasms
Granulocyte-Macrophage Progenitor Cells
Proteins
Frozen Sections
Bone Marrow Cells
Agar
Stem Cells
Monoclonal Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ghetie, M. A., May, R. D., Till, M., Uhr, J. W., Ghetie, V., Knowles, P. P., ... Thorpe, P. E. (1988). Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Research, 48(9), 2610-2617.

Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. / Ghetie, M. A.; May, R. D.; Till, M.; Uhr, J. W.; Ghetie, V.; Knowles, P. P.; Relf, M.; Brown, A.; Wallace, P. M.; Janossy, G.; Amlot, P.; Vitetta, E. S.; Thorpe, P. E.

In: Cancer Research, Vol. 48, No. 9, 1988, p. 2610-2617.

Research output: Contribution to journalArticle

Ghetie, MA, May, RD, Till, M, Uhr, JW, Ghetie, V, Knowles, PP, Relf, M, Brown, A, Wallace, PM, Janossy, G, Amlot, P, Vitetta, ES & Thorpe, PE 1988, 'Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy', Cancer Research, vol. 48, no. 9, pp. 2610-2617.
Ghetie, M. A. ; May, R. D. ; Till, M. ; Uhr, J. W. ; Ghetie, V. ; Knowles, P. P. ; Relf, M. ; Brown, A. ; Wallace, P. M. ; Janossy, G. ; Amlot, P. ; Vitetta, E. S. ; Thorpe, P. E. / Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. In: Cancer Research. 1988 ; Vol. 48, No. 9. pp. 2610-2617.
@article{67a10c5667654637b79fe79c3efc8b32,
title = "Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy",
abstract = "Ricin A chain-containing immunotoxin (IT-As) specific for the human B-cell antigens, CD22 and CD19, were constructed using the monoclonal antibodies, HD6 and HD37, respectively. IT-As were prepared by coupling intact antibodies, F(ab')2, or Fab' fragments to native or chemically deglycosylated ricin A chain. The IT-As were then evaluated for cytotoxicity to normal and neoplastic human B-cells in vitro with the major objective of appraising their suitability for in vivo therapy of human B-cell tumors. The IT-As prepared with both the HD6 and HD37 antibodies were specifically toxic to normal B-cells and to most of the neoplastic B-cell lines tested. However, the IT-As prepared from HD6 were generally more potent than those prepared from HD37. On Daudi cells, to which the two antibodies bound in similar numbers and with similar affinities, IT-As prepared with intact HD6 antibody or its Fab' fragment were 10-fold and 1.5- to 4-fold more potent, respectively, than the corresponding HD37 IT-As. The IT-As constructed from intact HD6 antibody and native or deglycosylated A chain reduced protein synthesis in Daudi cells by 50{\%} at a concentration of 1.2 x 10-11 M indicating that they were only 5-fold less toxic to the cells than ricin itself. Intact HD-37 IT-As produced equivalent inhibition of protein synthesis at 1.5 x 10-10 M. With both antibodies, IT-As constructed from the Fab' fragments were 10- to 20-fold less potent than their intact antibody counterparts. Different neoplastic B-cell lines varied in sensitivity to the IT-As. In most cases, their sensitivity correlated with the levels of CD19 and CD22 antigens expressed. Neither HD6 nor HD37 IT-As affected the ability of normal human bone marrow cells to form granulocyte-macrophage colony-forming units in soft agar, suggesting that both antigens are absent from these progenitor cells. Examination of sections of frozen human tissues using immunoperoxidase staining procedurs indicated that the antibodies did not bind to a panel of normal tissues lacking B-lymphocytes. These results suggest that HD6 and HD37 IT-As are candidates for in vivo therapy in humans with certain B-cell tumors. However, HD6 IT-As are more potent, reduce protein synthesis more completely, and hence appear to be the ITs of choice for treating tumors expressing the CD22 antigen.",
author = "Ghetie, {M. A.} and May, {R. D.} and M. Till and Uhr, {J. W.} and V. Ghetie and Knowles, {P. P.} and M. Relf and A. Brown and Wallace, {P. M.} and G. Janossy and P. Amlot and Vitetta, {E. S.} and Thorpe, {P. E.}",
year = "1988",
language = "English (US)",
volume = "48",
pages = "2610--2617",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy

AU - Ghetie, M. A.

AU - May, R. D.

AU - Till, M.

AU - Uhr, J. W.

AU - Ghetie, V.

AU - Knowles, P. P.

AU - Relf, M.

AU - Brown, A.

AU - Wallace, P. M.

AU - Janossy, G.

AU - Amlot, P.

AU - Vitetta, E. S.

AU - Thorpe, P. E.

PY - 1988

Y1 - 1988

N2 - Ricin A chain-containing immunotoxin (IT-As) specific for the human B-cell antigens, CD22 and CD19, were constructed using the monoclonal antibodies, HD6 and HD37, respectively. IT-As were prepared by coupling intact antibodies, F(ab')2, or Fab' fragments to native or chemically deglycosylated ricin A chain. The IT-As were then evaluated for cytotoxicity to normal and neoplastic human B-cells in vitro with the major objective of appraising their suitability for in vivo therapy of human B-cell tumors. The IT-As prepared with both the HD6 and HD37 antibodies were specifically toxic to normal B-cells and to most of the neoplastic B-cell lines tested. However, the IT-As prepared from HD6 were generally more potent than those prepared from HD37. On Daudi cells, to which the two antibodies bound in similar numbers and with similar affinities, IT-As prepared with intact HD6 antibody or its Fab' fragment were 10-fold and 1.5- to 4-fold more potent, respectively, than the corresponding HD37 IT-As. The IT-As constructed from intact HD6 antibody and native or deglycosylated A chain reduced protein synthesis in Daudi cells by 50% at a concentration of 1.2 x 10-11 M indicating that they were only 5-fold less toxic to the cells than ricin itself. Intact HD-37 IT-As produced equivalent inhibition of protein synthesis at 1.5 x 10-10 M. With both antibodies, IT-As constructed from the Fab' fragments were 10- to 20-fold less potent than their intact antibody counterparts. Different neoplastic B-cell lines varied in sensitivity to the IT-As. In most cases, their sensitivity correlated with the levels of CD19 and CD22 antigens expressed. Neither HD6 nor HD37 IT-As affected the ability of normal human bone marrow cells to form granulocyte-macrophage colony-forming units in soft agar, suggesting that both antigens are absent from these progenitor cells. Examination of sections of frozen human tissues using immunoperoxidase staining procedurs indicated that the antibodies did not bind to a panel of normal tissues lacking B-lymphocytes. These results suggest that HD6 and HD37 IT-As are candidates for in vivo therapy in humans with certain B-cell tumors. However, HD6 IT-As are more potent, reduce protein synthesis more completely, and hence appear to be the ITs of choice for treating tumors expressing the CD22 antigen.

AB - Ricin A chain-containing immunotoxin (IT-As) specific for the human B-cell antigens, CD22 and CD19, were constructed using the monoclonal antibodies, HD6 and HD37, respectively. IT-As were prepared by coupling intact antibodies, F(ab')2, or Fab' fragments to native or chemically deglycosylated ricin A chain. The IT-As were then evaluated for cytotoxicity to normal and neoplastic human B-cells in vitro with the major objective of appraising their suitability for in vivo therapy of human B-cell tumors. The IT-As prepared with both the HD6 and HD37 antibodies were specifically toxic to normal B-cells and to most of the neoplastic B-cell lines tested. However, the IT-As prepared from HD6 were generally more potent than those prepared from HD37. On Daudi cells, to which the two antibodies bound in similar numbers and with similar affinities, IT-As prepared with intact HD6 antibody or its Fab' fragment were 10-fold and 1.5- to 4-fold more potent, respectively, than the corresponding HD37 IT-As. The IT-As constructed from intact HD6 antibody and native or deglycosylated A chain reduced protein synthesis in Daudi cells by 50% at a concentration of 1.2 x 10-11 M indicating that they were only 5-fold less toxic to the cells than ricin itself. Intact HD-37 IT-As produced equivalent inhibition of protein synthesis at 1.5 x 10-10 M. With both antibodies, IT-As constructed from the Fab' fragments were 10- to 20-fold less potent than their intact antibody counterparts. Different neoplastic B-cell lines varied in sensitivity to the IT-As. In most cases, their sensitivity correlated with the levels of CD19 and CD22 antigens expressed. Neither HD6 nor HD37 IT-As affected the ability of normal human bone marrow cells to form granulocyte-macrophage colony-forming units in soft agar, suggesting that both antigens are absent from these progenitor cells. Examination of sections of frozen human tissues using immunoperoxidase staining procedurs indicated that the antibodies did not bind to a panel of normal tissues lacking B-lymphocytes. These results suggest that HD6 and HD37 IT-As are candidates for in vivo therapy in humans with certain B-cell tumors. However, HD6 IT-As are more potent, reduce protein synthesis more completely, and hence appear to be the ITs of choice for treating tumors expressing the CD22 antigen.

UR - http://www.scopus.com/inward/record.url?scp=0023886893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023886893&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 2610

EP - 2617

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -